Where Acylcarnitines (composite) is reported
Also listed as: Acylcarnitines; Fatty acid oxidation intermediates; Fatty acid oxidation — ME/CFS overlap
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Gulf War Illness | ↑ elevated | healthy Gulf War veteran controls | Fatigue, mitochondrial dysfunction | Gean et al. 2021 |
| ME/CFS | ↑ elevated | healthy controls | Mitochondrial dysfunction, PEM | Jinushi et al. 2023 |
Frequently asked questions
In which conditions is Acylcarnitines (composite) altered?
In the OSMF atlas Acylcarnitines (composite) is reported in Gulf War Illness, ME/CFS. It is elevated in 2 across 2 entries.
Does Acylcarnitines (composite) point to one specific diagnosis?
No. Because Acylcarnitines (composite) changes in several conditions (Gulf War Illness, ME/CFS), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
Is there a standard clinical test for Acylcarnitines (composite)?
The atlas entries for Acylcarnitines (composite) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal Acylcarnitines (composite) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.